Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
(World News USA)

Clinical Activity Observed in 43% of Evaluable Relapsed or Refractory AML and Higher-Risk MDS Patients, Including Improvement in Blood Counts, Reduction in Leukemic Blasts and One Marrow Complete Response As Defined by IWG Criteria Myeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients Activity As Single Agent, Coupled with Preclinical Combination Data, Support Ongoing Phase 2 Trial of SY-1425 in Combination with Other Therapies Initial Clinical Data from Cohorts Evaluating SY-1425 in Combination with a Hypomethylating Agent and with an Anti-CD38 Therapy Expected in 2018 Syros to Host Investor Event and Webcast on Monday, December 11 at 12:00 p.m. ET...